TriStar Health Partners

  • Home
  • About
    • TriStar
    • Team
  • News
  • Investment Strategy
    • Investment Strategy
    • Economic Development Fund – TN Investco
  • Portfolio
  • Contact

BioStable Science & Engineering Announces FDA Clearance of the HAART™ 300 Aortic Annuloplasty Device

March 27, 2017 By tstventures2015

BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device designed for aortic valve repair. BioStable expects the HAART 300 Aortic Annuloplasty Device to be available to select U.S. heart centers in the summer of 2017. (Read More)

Filed Under: News

Our Portfolio


VIEW MORE

Subscribe to News & Events

Contact Us

Thank you for your interest in TriStar Health Partners. If you have questions or need further information, please contact us!

TriStar Health Partners

3322 West End Ave, Suite 1100 | Nashville, TN 37203
615.515-9880

Copyright © 2023 TriStar Technology Ventures. All rights reserved (CC-licensed photos excepted).